Conference Proceedings
Latest findings from the breast cancer cohort in SUMMIT - a phase 2 'basket' trial of neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
Komal Jhaveri, Cristina Saura, Angel Guerrero-Zotano, Iben Spanggaard, Francois-Clement Bidard, Jonathan W Goldman, Jose A Garcia-Saenz, Andres Cervantes, Valentina Boni, John Crown, Adam Brufsky, Sherene Loi, Barbara Haley, Ingrid A Mayer, Stephen Chia, Janice Lu, James Waisman, Noa Efrat Ben-Baruch, Mark E Burkard, Jennifer M Suga Show all
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
Abstract
Abstract Background: HER2 mutations are oncogenic in hormone receptor positive (HR+) metastatic breast cancer (MBC), and may confer resistance to prior endocrine therapy but retain sensitivity to neratinib. Neratinib is an oral, irreversible, pan-HER tyrosine kinase inhibitor with clinical activity either as a single agent or in combination with fulvestrant in HER2-mutated, HER2-non-amplified MBC. Genomic analyses suggest that acquired resistance to neratinib can occur via additional HER2 alterations, which may alter HER2-pathway signaling. We investigated whether dual HER2-targeted therapy could improve clinical benefit in a cohort of patients with HER2-mutant, HR+ MBC treate..
View full abstract